25 January 2013
World-First Surgery: Robot Debuts at Tauranga Hospital
A new robotic surgical device which may change the nature of surgery was developed over four years in Silicon Valley,
USA and trialled in a world-first operation at Tauranga Hospital this week.
The connection between the two organisations is the head of the Bay of Plenty District Health Board Clinical School
Associate Professor, Peter Gilling, who has an international reputation for the surgical treatment of benign prostatic
hyperplasia (BPH) and works out of Tauranga.
BPH is an enlargement of the prostate gland and Dr Gilling said as many as a quarter of men older than 60 years have
this condition.
Working alongside his California-based colleagues Dr Gilling, performed the world-first surgery in Tauranga Hospital
this week on two men. The first to be treated was an 84 year old Mount Maunganui man. Dr Gilling said both men were
aware that they were making medical history and were excited to be part of the trial,
“They both stayed in hospital overnight and were discharged within 48 hours of admission,” he said.
“The Urology Research Team have undertaken this study in conjunction with the Clinical Trials Unit as part of the Bay of
Plenty District Health Board Clinical School,” he said. “BPH is a huge problem, and it is the first disease that this
new technology will be attacking.”
Dr Gilling said the technology has been developed as a solution for BPH a condition that increases the size of the
prostate, and can cause partial or sometimes virtually complete obstruction of the urethra. This leads to many urinary
complications and discomfort. It does not lead to cancer or increase the risk of cancer, and can be controlled with
medication. However, when the symptoms become intolerable it needs to be removed via surgery.
Most recently this procedure has been performed using thermal energy involving high powered lasers through the urethra.
However PROCEPT BioRobotics, the creators of this new technology, are hoping to change the nature of surgery by using
water instead.
Dr Gilling explained that this new technique cuts and cauterises using a waterjet as thin as a strand of hair, and a
very low powered blue light laser. This surgical robotic device removes tissue using high pressure water with a precise
and consistent fluid velocity rate.
PROCEPT BioRobotics flew their equipment over from America to undertake the operations.
“We have been working on this project for four years,” said Dr Nikolai Aljuri, Founder and CEO. “This live trial is the
most important day in the history of our company.”
“The use of water has many benefits,” said Dr Aljuri. “There will be no secondary damage from heat, as there is with
laser surgery, so there will be reduced complications and faster recovery time. It will also be very cost effective
compared to laser surgery, as laser uses hundreds of watts, whilst waterjet guided laser only uses a few watts.”
“Water has beautiful characteristics and is tissue selective,” said Dr Aljuri, Founder and CEO. “This new technology
called Aquablation is a very accurate and effective way of removing tissue, which will not only be better for patients,
but for urologists.”
Professor Rodney Perkins of Stanford University, the Chairman and Co-Founder of PROCEPT BioRobotics was very pleased
with how the first trial went, “We are pleased to be working with Peter Gilling, who is an outstanding contributor
worldwide to urology and a world-class urologist. We appreciate the cooperation we’ve had in New Zealand and appreciate
their contribution towards developing new innovations in urology so that they can be brought to the public more
rapidly.”
After performing the world-first trial this week, PROCEPT BioRobotics will now do a pilot study on ten additional
patients. If this is successful they will then do a larger study, before making the product commercially available.
How it works:
• The doctor takes measurements to determine how much tissue to remove and inputs it in a handheld computer.
• A robotic arm connected to a telescope is inserted into the patient.
• Jets of water carry out the rest of the operation automatically.
• A very low powered laser can be used to stop any bleeding if necessary.
•
ENDS